ArticleGene therapy2004
Potential therapeutic applications of recombinant, invasive E. coli.
Article in Gene therapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 70 citations in OpenAlex.
- Gut Microbiota-Based Immunotherapy: EngineeredMedicina (Kaunas, Lithuania) · 2025Article
- Evolution and synthetic biology.Current opinion in microbiology · 2023Review
- Improvement in the production of the human recombinant enzyme N-acetylgalactosamine-6-sulfatase (rhGALNS) in Escherichia coli using synthetic biology approaches.Scientific reports · 2017Article
- Review
- Improved Escherichia coli Bactofection and Cytotoxicity by Heterologous Expression of Bacteriophage ΦX174 Lysis Gene E.Molecular pharmaceutics · 2015Article
- PEGylated cationic polylactides for hybrid biosynthetic gene delivery.Molecular pharmaceutics · 2015Article
- Impediments to enhancement of CPT-11 anticancer activity by E. coli directed beta-glucuronidase therapy.PloS one · 2015Article
- Hybrid biosynthetic gene therapy vector development and dual engineering capacity.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Polymyxin B treatment improves bactofection efficacy and reduces cytotoxicity.Molecular pharmaceutics · 2013Article
- Patterning bacterial communities on epithelial cells.PloS one · 2013Article
- Surface display of N-terminally anchored invasin by Lactobacillus plantarum activates NF-κB in monocytes.Applied and environmental microbiology · 2012Article
- Article
- Iron-regulated lysis of recombinant Escherichia coli in host releases protective antigen and confers biological containment.Infection and immunity · 2011Article
- Proliferation behavior of E. coli in a three-dimensional in vitro tumor model.Integrative biology : quantitative biosciences from nano to macro · 2011Article
- Direct injection of functional single-domain antibodies from E. coli into human cells.PloS one · 2010Article
- The oncopathic potency of Clostridium perfringens is independent of its alpha-toxin gene.Human gene therapy · 2009Article
- Evaluation of recombinant invasive, non-pathogenic Eschericia coli as a vaccine vector against the intracellular pathogen, Brucella.Journal of immune based therapies and vaccines · 2009Article
- Therapeutic potential of replication-selective oncolytic adenoviruses on cells from familial and sporadic desmoid tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2008Article
- A genetically enhanced anaerobic bacterium for oncopathic therapy of pancreatic cancer.Journal of the National Cancer Institute · 2008Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An invasive Escherichia coli expressing the inv gene from Yersinia pseudotuberculosis was used as a vector for protein delivery to mammalian epithelial cells. Upon incubation with beta1-integrin-expressing mammalian cells, the bacteria are internalized, allowing bacteria-encoded proteins to function from within the mammalian cell. These bacteria are eventually processed in the host phagosome where they are destroyed. Expression of listeriolysin O from Listeria monocytogenes in the bacterium and its subsequent release into the phagosome triggers the breakdown of the membrane, allowing the release of the bacterial content into the cytosol of host cells. Using this vector, we demonstrate delivery of a gene and intact, functional proteins into mammalian cells in which beta1-integrin is expressed and accessible. At a ratio of bacteria/mammalian cells compatible with the survival of the mammalian cells, protein delivery can be observed in the entire cell population in vitro, while gene transfer is far less efficient. Protein delivery can also be achieved in vivo in mouse tumour models and can be detected at least 96 h after inoculation. Functional, natural E. coli proteins are delivered in the process and can provide therapeutic benefit in vivo, when associated with prodrugs. This therapeutic effect is associated with infiltration of neutrophils, eosinophils, macrophages and to a lesser extent dendritic cells in the tumour mass.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.